COMMUNIQUÉS West-GlobeNewswire

Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
12/08/2026
Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX [...]
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
12/08/2026
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing [...]
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12/08/2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases [...]
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12/08/2026
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 [...]
BioPorto A/S to host an investor webcast on the results for the first half of 2026
12/08/2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO [...]
Anteris Technologies Announces Results for the Second Quarter of 2026
12/08/2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, [...]
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
12/08/2026
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference ( [...]
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
12/08/2026
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic [...]
NovelMed Advances NM5072 for Multiple Ocular Disorders
11/08/2026
Key Highlights Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single [...]
Five Years of Unprecedented Growth: TimelyCare Redefines Student Well-Being
11/08/2026
Latest Inc. 5000 ranking cements TimelyCare’s position as a trusted, high-impact partner for educational communities. Fort Worth, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- TimelyCare, education’s most trusted virtual care [...]
Rampart Withdraws Appeal of USPTO’s Invalidation Decision
11/08/2026
ST. PAUL, Minn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Egg Medical announced today that Rampart IC, LLC (“Rampart”) withdrew its appeal of the USPTO’s reexamination decision that the claims of Rampart’s U.S. Patent No. 11, [...]
ASHA Names 2026 Media Champion Award Recipients
11/08/2026
Rockville, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The American Speech-Language-Hearing Association (ASHA) announced the recipients of ASHA’s 2026 Media Champion Awards today. These awards recognize media outlets, ASHA [...]
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08/2026
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway [...]
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
11/08/2026
Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 [...]
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026 Continues pre-launch [...]
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
11/08/2026
Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially First GenesisX robotic system purchase by US hospital to be installed this fall Multiple Synchrony digital operating room systems sold and [...]
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
11/08/2026
Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite [...]
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
11/08/2026
WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti- [...]
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
11/08/2026
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination ERAS-0015 [...]

Pages